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Background: Sunitinib malate is an oral, multitargeted tyrosine kinase 
inhibitor of VEGFRs, PDGFRs, KIT, RET, and FLT3. In a multicenter 
phase II trial of sunitinib administered on a 4/2 schedule (4 weeks on 
treatment followed by 2 weeks off) in recurrent advanced NSCLC, 11% 
of patients achieved a partial response (PR; Socinski, ESMO 2006). We 
report results from a planned extension of this phase II study, which 
investigated the efﬁcacy and safety of sunitinib given on a continuous 
dosing schedule.
Methods: Patient eligibility criteria included stage IIIB/IV NSCLC; 
failure of 1–2 prior chemotherapy regimens; ECOG PS ≤1; and ad-
equate organ function. Patients with brain metastases or recent gross 
hemoptysis were excluded. Patients received oral sunitinib 37.5 mg/day 
continuously in repeated 4-week cycles. The primary endpoint was 
the objective response rate to sunitinib (as per RECIST). Secondary 
endpoints included progression-free survival (PFS), overall survival 
(OS), and safety.
Results: Forty-seven patients were enrolled and treated with sunitinib 
on the continuous dosing schedule and started a median of 3 cycles 
(range 1–12). Baseline characteristics comprised median age 60 years 
(range 37–81); male 57%; ECOG PS 0/1/2 49%/49%/2%; adenocar-
cinoma 53%, squamous cell carcinoma 15%, other 32%; number of 
metastatic sites 0/1/2/≥3 2%/23%/38%/36%. Preliminary efﬁcacy data 
are available. One patient (2%) had a conﬁrmed PR and 8 patients 
(17%) had stable disease >3 months. Median PFS was 12.3 weeks 
(95% CI: 8.9–16.0); median OS had not been reached at the time of 
analysis. Sunitinib was generally well tolerated, with adverse events 
(AEs) usually managed by dose interruption or modiﬁcation. Dosing 
was interrupted in 24 patients (51%; this interruption was because 
of an AE in 20 patients [43%]). The dose was reduced to 25 mg/day 
in 14 patients (30%), and increased to 50 mg/day in 1 patient (2%). 
Fourteen patients (30%) had an AE that led to permanent withdrawal 
of sunitinib. AEs were predominantly mild to moderate; those reported 
most commonly were fatigue/asthenia (62%), pain/myalgia (55%), 
nausea/vomiting (43%), dyspnea (38%), diarrhea (36%), and stomatitis/
mucosal inﬂammation (32%). Grade ≥3 AEs included fatigue/asthenia 
(17%), dyspnea (9%), hypertension (6%), hypoxia (6%), and hemopty-
sis (2%). Serious AEs that were considered treatment-related included 
congestive heart failure (1 patient, who died following the onset of this 
AE), gastrointestinal bleeding (1 patient), hypomagnesemia (1 patient), 
and hypoxic respiratory failure (1 patient). 
Conclusions: Continuous daily sunitinib dosing has an acceptable 
safety proﬁle in patients with previously-treated, advanced NSCLC. 
Preliminary response data show that continuous dosing is active in this 
population, with 1 PR and a median PFS of 12.3 weeks. These results 
support further study of continuous dosing of sunitinib in combination 
with other treatments for NSCLC.
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Background: Lung and esophageal toxicity is regarded the main toxic-
ity in radical radiotherapy of NSCLC, but cardiac toxicity may be an 
equal risk factor. We have therefore performed a retrospective analysis 
of locally advanced NSCLC treated at our institution.
Methods: From September 1995 to February 2005 206 patients with 
inoperable non-small cell lung cancer stage IIB-IIIB received radical 
3-D conformal radiotherapy in planned doses 60 to 66 Gy in 30 to 33 
fractions. The dose plans were re-analyzed with regard to mean deliv-
ered dose (MDD) to the left ventricles (LV), both ventricles (BV), and 
the whole heart (WH). 
Results: 201 patients fulﬁlled the scheduled radiotherapy in excess 
of 60 Gy or more and in 200 of the cases data on MDD was obtain-
able. Minimum follow-up was 2 years. The median, 2 year and 5 year 
survival were 16.9 mths, 36% and 14%. The median MDD to the LV, 
BV, and WH was 8.05, 9.15, and 16.40 Gy, respectively, and the 75% 
quartile MDD was 16.35, 18.35, and 26.70 Gy.
When overall survival was analyzed in univariate analyses with the 
patient grouped according to quartiles of MDD, the patients receiving a 
dose above the 75% quartile to LV, BV, and WH had signiﬁcant poorer 
overall survival than patients receiving lesser doses. There were no sig-
niﬁcant differences in survival between the patients in 3 lower quartiles 
of MDD. As of March 1st, 2007, 174 of the patients had died, 154 due 
to recurrent lung cancer and 20 due to other causes, but this pattern was 
not associated with high MDD. In Cox-analyses MDD (>75% quartile 
limit), gross tumor volume (GTV>125 mL), lung dose (V20 ≥ 40%) 
were independent signiﬁcant factors (p<0.05) indicating poor overall 
survival. Dose to BV were superior to dose to WH and LV in predicting 
survival. 
Conclusions: In a series of NSCLC patients treated with 3-D confor-
mal radiotherapy a high mean dose to the heart was associated with ex-
cess mortality. Dose to the WH were no better to predict poor survival 
than dose to ventricles
